Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. September 2020 17:18 ET | Quelle: 89bio, Inc.

89bio to Present at Upcoming Investor Conference

SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
16. September 2020 20:51 ET | Quelle: 89bio, Inc.

89bio Announces Pricing of Upsized Public Offering of Common Stock

SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
14. September 2020 17:21 ET | Quelle: 89bio, Inc.

89bio Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
14. September 2020 07:01 ET | Quelle: 89bio, Inc.

89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH

All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and...
13. September 2020 19:53 ET | Quelle: 89bio, Inc.

89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH

SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study...
03. September 2020 08:30 ET | Quelle: 89bio, Inc.

89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia

SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
13. August 2020 16:05 ET | Quelle: 89bio, Inc.

89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 - - BIO89-100’s Phase 2 SHTG trial is expected to be initiated in Q3 - SAN FRANCISCO, Aug. 13, 2020...
03. August 2020 16:05 ET | Quelle: 89bio, Inc.

89bio to Present at Upcoming Investor Conferences

SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
13. Juli 2020 10:17 ET | Quelle: 89bio, Inc.

89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
07. Juli 2020 21:30 ET | Quelle: 89bio, Inc.

89bio Announces Pricing of Upsized Public Offering of Common Stock

SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...

Vorherige Seite